MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

MDT

95.97

-0.18%↓

137.66

+1.08%↑

VEEV

219.44

-1.64%↓

HQY

91.05

-0.5%↓

PHR.US

16.26

-3.79%↓

Home・Akciju saraksts・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

27.04

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

26.44

Max

27.38

Galvenie mērījumi
By Trading Economics
Ienākumi	-10M -67M
Peļņas marža	-7,753.425
Darbinieki	186
EBITDA	-9.8M -73M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+102.5% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	224M 1.7B
Iepriekšējā atvēršanas cena	27.04
Iepriekšējā slēgšanas cena	27.04

Ziņu noskaņojums

By Acuity

50%

141 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

18.91 / 20.63 Atbalsts un pretestība

Celldex Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 2. janv. 22:45 UTC

Galvenie tirgus virzītāji

GH Research Shares Up, Plans to Provide Update on New Drug Application

2026. g. 2. janv. 22:13 UTC

Tirgus saruna

Peļņas

Tesla Seen As Quiet on Artificial-Intelligence Efforts -- Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2026. g. 2. janv. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 21:07 UTC

Peļņas

Tesla Stock Pops and Drops After Fourth-Quarter Deliveries. -- Barrons.com

2026. g. 2. janv. 20:09 UTC

Tirgus saruna

Oil Futures Slip in First Trading Day of the Year -- Market Talk

2026. g. 2. janv. 19:48 UTC

Tirgus saruna

U.S. Natural Gas Futures Kick Off 2026 With A Loss -- Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 2. janv. 18:53 UTC

Tirgus saruna

Mexico PMIs Show Manufacturing Weakness in December -- Market Talk

2026. g. 2. janv. 17:56 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Meta's Manus Acquisition May Help Fill AI Monetization Gap -- Market Talk

2026. g. 2. janv. 17:50 UTC

Tirgus saruna

Apparel Industry Seen With Strength Across Income Levels -- Market Talk

2026. g. 2. janv. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 2. janv. 16:33 UTC

Tirgus saruna

Remittances to Mexico Fell 5.7% in November -- Market Talk

2026. g. 2. janv. 16:18 UTC

Tirgus saruna

Tesla Dethroned as World's Largest EV Maker -- Market Talk

2026. g. 2. janv. 15:48 UTC

Peļņas

Software Has Been Battered by AI. Shopify, Veeva, and 3 More Stocks to Play a Turnaround. -- Barrons.com

2026. g. 2. janv. 15:17 UTC

Tirgus saruna

Tesla Expected to Make Its Switch to Robotics, AI in 2026 -- Market Talk

2026. g. 2. janv. 15:01 UTC

Tirgus saruna

Sable Seen Nearing Production Relaunch After Court Ruling -- Market Talk

2026. g. 2. janv. 15:00 UTC

Peļņas

The Maker of Biscoff Cookies Bets on a Global Expansion -- WSJ

2026. g. 2. janv. 14:56 UTC

Tirgus saruna

Tesla's Sales Drop Was Better Than Feared -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Capstone Copper's Mantoverde Strike Could Be Costly -- Market Talk

2026. g. 2. janv. 14:20 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 2. janv. 14:13 UTC

Tirgus saruna

Oil Futures Open Year Lower on Oversupply Concerns -- Market Talk

2026. g. 2. janv. 13:39 UTC

Tirgus saruna

U.S. Natural Gas Futures Open Year Lower -- Market Talk

2026. g. 2. janv. 13:01 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Unicredit Could Buy Delfin's BMPS Stake, Launch Full Takeover, Equita Says -- Market Talk

2026. g. 2. janv. 12:45 UTC

Tirgus saruna

Emerging-Market Dollar Bonds Record Strong Returns in 2025 -- Market Talk

2026. g. 2. janv. 11:48 UTC

Tirgus saruna

European Gas Climbs as Cold Weather Bites -- Market Talk

2026. g. 2. janv. 11:36 UTC

Tirgus saruna

Treasury Yields, Dollar Edge Higher as Near-Term Fed Rate Cut Looks Unlikely -- Market Talk

2026. g. 2. janv. 11:30 UTC

Tirgus saruna

Copper Rally Continues, Spurred by Supply Shocks -- Market Talk

2026. g. 2. janv. 11:29 UTC

Tirgus saruna

Dollar Rises After Posting Worst Year Since 2017 -- Market Talk

2026. g. 2. janv. 11:15 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Celldex Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

102.5% augšup

Prognoze 12 mēnešiem

Vidējais 55 USD 102.5%

Augstākais 90 USD

Zemākais 24 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Celldex Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Celldex Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

18.91 / 20.63Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

141 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.